Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Jason Yang, Ziping Wang et al.|Nature Cancer|2023Cited by 34
Single-neutron removal from <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mmultiscripts><mml:mi mathvariant="normal">C</mml:mi><mml:mprescripts/><mml:none/><mml:mrow><mml:mn>14</mml:mn><mml:mo>,</mml:mo><mml:mn>15</mml:mn><mml:mo>,</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:mmultiscripts></mml:math> near 240 MeV/nucleonY. Sun, Limin Duan, S. T. Wang et al.|Physical Review C|2021Cited by 19
Parental preconception BMI and risk of adverse birth outcomes in 8 million parent–child triads: a nationwide population-based cohort study in ChinaBuyun Liu, Xu Ma, Yue Cheng et al.|The Lancet Diabetes & Endocrinology|2025Cited by 11